The Cage system can be utilized at one or two contiguous levels from L2-S1 from a posterior approach for lumbar interbody fusion. The device is comprised of two footprints with three varying degrees of lordosis and graft windows for maximum endplate-to-endplate contact. The product is currently in limited, controlled release and is targeted for full commercial launch by the fourth quarter.
Read the company news release about Medyssey Spine’s Cage System.
Read other coverage about FDA clearances:
– Integra LifeSciences Receives FDA 510(k) Clearance for 3 Spine Devices
– 22 Spine Devices Receive FDA 510(k) Clearance in March
– 56 Orthopedic and Spine Devices Receive FDA 510(k) Clearance in March
